Cargando…

A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer

Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rades, Dirk, Zwaan, Inga, Idel, Christian, Pries, Ralph, Bruchhage, Karl L., Hakim, Samer G., Yu, Nathan Y., Soror, Tamer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381843/ https://www.ncbi.nlm.nih.gov/pubmed/37511733 http://dx.doi.org/10.3390/jpm13071120

Ejemplares similares

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

First Results of Concurrent Chemoradiation with Two Courses of 5 × 25 mg/m(2) Cisplatin for Locally Advanced Head and Neck Cancer
por: Zwaan, Inga, et al.
Publicado: (2023)

Smoking-, Alcohol-, and Age-Related Alterations of Blood Monocyte Subsets and Circulating CD4/CD8 T Cells in Head and Neck Cancer
por: Idel, Christian, et al.
Publicado: (2022)

Salvage High-Dose-Rate Interventional Radiotherapy (Brachytherapy) Combined with Surgery for Regionally Relapsed Head and Neck Cancers
por: Soror, Tamer, et al.
Publicado: (2023)

Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer – results of a randomized phase III trial (RAREST-02)
por: Rades, Dirk, et al.
Publicado: (2022)

Increased Abundances of CD16(+) Non-Classical Monocytes Accompany with Elevated Monocytic PD-L1 and CD4(+) T Cell Disturbances in Oropharyngeal Cancer
por: Idel, Christian, et al.
Publicado: (2022)

Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas
por: Idel, Christian, et al.
Publicado: (2021)

Plasma‑derived CD16 exosomes and peripheral blood monocytes as correlating biomarkers in head and neck cancer
por: Theodoraki, Marie-Nicole, et al.
Publicado: (2023)

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC
por: von Bernuth, Amelie, et al.
Publicado: (2023)

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
por: Möckelmann, Nikolaus, et al.
Publicado: (2016)

CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer
por: Jagomast, Tobias, et al.
Publicado: (2022)

Immunologic “Cold” Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

Radiotherapy related skin toxicity (RAREST-01): Mepitel® film versus standard care in patients with locally advanced head-and-neck cancer
por: Narvaez, Carlos, et al.
Publicado: (2018)

Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
por: Jeong, Il Seok Daniel, et al.
Publicado: (2020)

Randomized trial on acute toxicities of weekly vs three‐weekly cisplatin‐based chemoradiation in head and neck cancer
por: Ameri, Ahmad, et al.
Publicado: (2021)

Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers
por: Rades, Dirk, et al.
Publicado: (2016)

Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiation
por: Soror, Tamer, et al.
Publicado: (2023)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

Prognostic impact of the loss of E-cadherin and de novo expression of N-cadherin at the invasive front of primary and recurrent oral squamous cell carcinoma
por: Hakim, Samer George, et al.
Publicado: (2023)

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC
por: Paulsen, Finn-Ole, et al.
Publicado: (2020)

NR2F6 as a Prognostic Biomarker in HNSCC
por: Klapper, Luise, et al.
Publicado: (2020)

TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC
por: Klapper, Luise, et al.
Publicado: (2022)

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
por: Jun, H J, et al.
Publicado: (2008)

Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin
por: van der Vorst, Maurice J. D. L., et al.
Publicado: (2019)

Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers
por: Mak, Milena Perez, et al.
Publicado: (2020)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients
por: Nogueira, Guilherme Augusto Silva, et al.
Publicado: (2018)

Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma
por: Ahn, Dongbin, et al.
Publicado: (2020)

Management of Chemoradiation-Induced Mucositis in Head and Neck Cancers With Oral Glutamine
por: Pattanayak, Lucy, et al.
Publicado: (2016)

Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial
por: Vreugdenhil, M., et al.
Publicado: (2021)

A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone
por: Huttenlocher, Stefan, et al.
Publicado: (2014)

Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer
por: Han, Hye Ri, et al.
Publicado: (2021)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

Narrative review of the management of oral mucositis during chemoradiation for head and neck cancer
por: Judge, Lauren F., et al.
Publicado: (2021)

Intravenous fluids for pain management in head and neck cancer patients undergoing chemoradiation
por: Rivers, Charlotte I., et al.
Publicado: (2021)

Effect of vocal rehabilitation after chemoradiation for non-laryngeal head and neck cancers
por: Sreenivas, Athulya, et al.
Publicado: (2021)

The Effect of Radiation and Chemoradiation Therapy on the Head and Neck Mucosal Microbiome: A Review
por: Zagury-Orly, Ivry, et al.
Publicado: (2021)

Assessment of the Role of Gefitinib With Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
por: Prajapati, Raju, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qoruh6b9ghhu4o409pjs2l789s